rosiglitazone has been researched along with Cardiovascular Diseases in 222 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 123 (55.41) | 29.6817 |
| 2010's | 94 (42.34) | 24.3611 |
| 2020's | 5 (2.25) | 2.80 |
| Authors | Studies |
|---|---|
| Li, A; Li, XM; Liu, MQ; Song, CG; Wu, K; Wu, ZJ; Xu, ZL | 1 |
| Califf, RM; Demets, D; George, JT; Gerstein, HC; Granger, C; Green, JB; Hobbs, T; Holman, RR; Lawson, FC; Leiter, LA; McGuire, DK; McMurray, J; Pagidipati, NJ; Pfeffer, MA; Reusch, J; Riesmeyer, JS; Roe, MT; Rosenberg, Y; Sharma, A; Temple, R; Wiviott, S | 1 |
| Bu, X; Duan, X; He, Y; Ming, X; Sun, S; Wu, Q; Yan, F; Zhu, H | 1 |
| Bracken, MB; Cheng, D; Desai, M; Grossetta Nardini, HK; Krumholz, HM; Lin, H; Ross, JS; Wallach, JD; Wang, K; Zhang, AD | 1 |
| Atar, D; Marciniak, TA; Serebruany, V | 1 |
| Amoroso, R; Maccallini, C; Mollica, A | 1 |
| Azhar, S; Bittner, S; Han, L; Kraemer, FB; Shen, WJ | 1 |
| Liu, J; Wang, LN | 3 |
| Bacha, F; Bjornstad, P; El Ghormli, L; Gidding, SS; Levitsky, LL; Levitt Katz, LE; Lima, JAC; Lynch, J; Tryggestad, JB; Weinstock, RS | 1 |
| Cheng, D; Gao, H; Li, W | 1 |
| Al-Jabri, B; Bajaj, HS; Verma, S | 1 |
| Bennett, PH; Crandall, JP; Edelstein, SL; Goldberg, RB; Kahn, SE; Knowler, WC; Mather, KJ; Mudaliar, S; Nathan, DM; Orchard, TJ; Temprosa, M; White, NH | 1 |
| Bahn, G; Koska, J; Reaven, PD; Saremi, A; Yamashita, S | 1 |
| Hiatt, WR; Kaul, S; Smith, RJ | 1 |
| Moreno, E; Negrín, MA; Vázquez-Polo, FJ | 1 |
| Barendregt, JJ; Doi, SA; Furuya-Kanamori, L; Stone, JC | 1 |
| Abete, P; Bellia, A; Cacciatore, F; Capuani, B; Dave, KR; De Marchis, ML; Della-Morte, D; Donadel, G; Dong, C; Ferroni, P; Fogliame, G; Guadagni, F; Lauro, D; Pacifici, F; Palmirotta, R; Pastore, D; Pileggi, A; Rehni, AK; Ricordi, C; Roselli, M; Rundek, T; Sbraccia, P | 1 |
| Dangi-Garimella, S | 1 |
| Ciaraldi, TP; Samad, F; Wang, J | 1 |
| Abraira, C; Bahn, G; Duckworth, W; Emanuele, N; Florez, H; Hayward, R; Marks, J; Moritz, T; Reaven, PD; Reda, D; Warren, S | 1 |
| Hsu, JC; Lu, CY; Ross-Degnan, D; Wagner, AK; Zhang, F | 1 |
| Meyer, RJ | 1 |
| Alves, C; Batel-Marques, F; Mendes, D | 1 |
| Ginsberg, H; He, Y; Heinecke, JW; Oda, M; Reyes-Soffer, G; Ronsein, GE | 1 |
| Shuster, JJ; Walker, MA | 1 |
| Calingaert, B; Margulis, AV; Perez-Gutthann, S; Pladevall, M; Riera-Guardia, N; Varas-Lorenzo, C | 1 |
| Chen, YT; Liu, YM; Ou, HT; Wu, JS | 1 |
| Fu, H; Gaydos, BL; Heine, RJ; Hoogwerf, BJ; Manner, DH; Moscarelli, E | 1 |
| Holzhauer, B | 1 |
| Abbasi, F; Chen, YD; Farin, HM; Lamendola, C; Reaven, GM | 1 |
| Hernandez, AV; Ioannidis, JP; Kattan, MW; Walker, E | 1 |
| Ajjan, RA; Grant, PJ | 1 |
| Hirschberg, DL; Huang, M; Li, Z; Nestorova, G; Quertermous, T; Tsao, P; Wagner, R; Wilson, KD; Wu, JC; Yock, PG; Yue, P | 1 |
| Janez, A; Jensterle, M; Keber, I; Kocjan, T; Pfeifer, M; Prezelj, J; Sebestjen, M | 1 |
| Lasaridis, AN; Sarafidis, PA; Stafylas, PC | 2 |
| Derosa, G; Salvadeo, SA | 1 |
| Diamond, GA; Kaul, S | 4 |
| Loke, YK; Singh, S | 1 |
| Mannucci, E; Marchionni, N; Monami, M | 2 |
| Felson, S; Fisher, E; Schwartzbard, A; Zinn, A | 1 |
| Besler, C; Doerries, C; Giannotti, G; Landmesser, U; Lüscher, TF | 1 |
| Kittisupamongkol, W | 1 |
| Luan, FL; Nguyen, K | 1 |
| Cai, T; Cremieux, PY; Pfeffer, MA; Piankov, N; Tian, L; Wei, LJ | 1 |
| Waksman, JC | 1 |
| Chalasani, N; Vuppalanchi, R | 1 |
| Abraira, C; Davis, SN; Duckworth, W; Emanuele, N; Goldman, S; Hayward, R; Henderson, WG; Huang, GD; Marks, J; McCarren, M; Moritz, T; Reaven, PD; Reda, D; Vitek, ME; Warren, SR; Zieve, FJ | 1 |
| Abdullah, SM; Ayers, CR; McGavock, JM; McGuire, DK; See, R; Snell, PG; Szczepaniak, LS | 1 |
| Bakris, GL; Kalaitzidis, RG; Sarafidis, PA | 1 |
| Abbasi, F; Lima, NK; Reaven, GM | 1 |
| Strahlman, E | 1 |
| Divine, G; Habib, ZA; Havstad, SL; Krajenta, R; Lanfear, DE; Pladevall, M; Tang, J; Tzogias, L; Wells, K; Williams, LK | 1 |
| Derks, M; Fowler, S; Kuhlmann, O | 1 |
| Ambery, P; Cobitz, AR | 1 |
| Albert, JM; Bailie, GR; Blayney, MJ; Goodkin, DA; Pisoni, RL; Port, FK; Ramirez, SP; Tentori, F; Wolfe, RA; Young, EW | 1 |
| Gomes, T; Juurlink, DN; Lipscombe, LL; Mamdani, MM | 1 |
| Luan, FL | 1 |
| George, J; Hannah, S; Lang, CC | 1 |
| Barnett, AH | 1 |
| Simon, D | 1 |
| Hanefeld, M | 3 |
| Armor, B; Burt, R; Townsend, S | 1 |
| Gore, MO; McGuire, DK | 1 |
| Chen, PF; Hsiao, FY; Huang, WF; Kuo, KN; Tsai, YW; Wen, YW | 1 |
| Brown, GE; Edwards, AL; Ghali, WA; Johnson, JA; Lewin, AM; Rabi, DM | 1 |
| Mannucci, E; Monami, M | 1 |
| Alevizos, M; Angelopoulou, N; Athanasiadou, Z; Iliadis, F; Kadoglou, NP; Kapelouzou, A; Karayannacos, PE; Liapis, CD; Sailer, N; Vitta, I; Vrabas, IS | 1 |
| Jazet, IM; Meinders, AE | 1 |
| Psaty, BM | 1 |
| Aquilante, CL; Knutsen, SD; Kosmiski, LA; Rome, LC; Zineh, I | 1 |
| Krumholz, HM | 1 |
| Caveda, E; Rodriguez, A; Simó, R | 1 |
| Bolger, AF; Eckel, RH; Giugliano, RP; Herrington, D; Kaul, S | 1 |
| Aguila, MB; Mandarim-de-Lacerda, CA; Torres, Tda S | 1 |
| Tanne, JH | 1 |
| Dushinat, M; Friedman, N; Halkin, H; Katzir, I; Kokia, E; Kurnik, D; Loebstein, R; Lomnicky, Y; Silverman, B; Vesterman-Landes, J | 1 |
| Farkouh, ME; Fuster, V | 3 |
| Bilik, D; Brown, MB; Crosson, JC; Herman, WH; Hsiao, VC; Karter, AJ; Lasser, NL; Mangione, CM; Marrero, DG; McEwen, LN; Selby, JV; Tseng, CW | 1 |
| Cai, T; Parast, L; Ryan, L | 1 |
| Roehr, B | 1 |
| Drazen, JM; Wood, AJ | 1 |
| Kean, S | 1 |
| Nissen, SE; Wolski, K | 2 |
| Davis, TM; Prins, JB | 1 |
| Krumholz, H; Lehman, R; Yudkin, JS | 1 |
| Freemantle, N | 1 |
| Cohen, D | 1 |
| Bloomgarden, Z; Handelsman, Y | 1 |
| Bloomgarden, Z | 1 |
| Johansen, K | 1 |
| Hamburg, M; Sharfstein, JM; Woodcock, J | 1 |
| Riddle, MC | 1 |
| Dogra, V; El-Bejjani, D; Harrill, D; Hileman, C; McComsey, GA; O'Riordan, MA; Rizk, N; Ross, AC; Storer, N; Tungsiripat, M | 1 |
| Chilton, RJ; Schernthaner, G | 1 |
| Baker, R; Philpott, S | 1 |
| Bashir, M; Idrees, M; Khan, RU; Malik, SA; Rahman, IU | 1 |
| Mayor, S | 1 |
| Russo, M; Salas, SP | 1 |
| Claggett, B; Wei, LJ | 1 |
| Lipska, KJ; Ross, JS | 1 |
| Arslanian, S; Lee, S; Sutton-Tyrrell, K; Tfayli, H; Ulnach, JW | 1 |
| Montori, VM; Shah, ND | 1 |
| Erem, C; Fidan, E; Karahan, C; Kocak, M; Onder Ersoz, H; Yilmaz, H; Yilmaz, M | 1 |
| Hurren, KM; Jaber, LA; Taylor, TN | 1 |
| McDonald, C | 1 |
| Heazlewood, VJ | 1 |
| Koch, A | 1 |
| Egidi, G; Popert, U | 1 |
| Balakhonova, TV; Blinova, IV; Chernukha, GE; Karpov, IuA | 1 |
| Winterstein, AG | 1 |
| Heckbert, SR; Schambelan, M; Winterstein, AG | 1 |
| Traynor, K | 1 |
| Gram, J; Henriksen, JE; Juhl, HF; Nybo, M; Olesen, M; Preil, SR; Rasmussen, LM; Yderstraede, K | 1 |
| Itoh, N; Ohkura, N; Oishi, K; Tomita, T | 1 |
| Jungbauer, A; Liebner, F; Zoechling, A | 1 |
| Barboza, J; Sando, KR; Taylor, J; Willis, C | 1 |
| Derosa, G | 1 |
| Afzal, R; Bosch, J; Dagenais, G; Diaz, R; Gerstein, H; Holman, R; Probstfield, J; Punthakee, Z; Ramachandran, A; Riddle, M; Rydén, LE; Yusuf, S; Zinman, B | 1 |
| Bao, Y; Jia, W; Lu, J; Zhou, J; Zhou, M | 1 |
| Amin, F; Idrees, M; Jan, NU; Khan, MI; Khan, RU; Salman, M; ur Rahman, I | 1 |
| Abdullah, SM; Ayers, CR; de Lemos, JA; Drazner, MH; Gore, MO; McGavock, J; McGuire, DK; See, R; Szczepaniak, LS | 1 |
| Chang, YW; Chen, WL; Chou, CC; Kao, TW; Loh, CH; Wang, CC | 1 |
| Huang, TH; Roufogalis, BD | 1 |
| Gallagher, AM; Leufkens, HG; Seabroke, S; Smeeth, L; van Staa, TP | 1 |
| Lane, PW | 1 |
| Ciudin, A; Hernandez, C; Simó, R | 1 |
| Grayson, BE; Herman, JP; Jones, KR; Ryan, KK; Schneider, AL; Seeley, RJ; Ulrich-Lai, YM; Woods, SC | 1 |
| Wilding, JP | 1 |
| Home, P | 1 |
| Atar, D; Serebruany, VL | 1 |
| Leal, I; Oteri, A; Romio, SA; Schuemie, M; Sturkenboom, M; Trifirò, G | 1 |
| Chen, X; Yang, L; Zhai, SD | 1 |
| Chen, H; Freed, MI; Greenberg, AS; Haffner, SM; Weston, WM; Williams, K | 1 |
| Tuepker, J | 1 |
| Diamant, M; Heine, RJ | 1 |
| Haffner, SM | 1 |
| Chilton, RJ; Stolar, MW | 1 |
| Asnani, S; DeSouza, C; Fonseca, V; Gilling, L; Suwattee, P | 1 |
| Badiwala, MV; Fedak, PW; Kuliszewski, MA; Kutryk, MJ; Li, SH; Mickle, DA; Stewart, DJ; Szmitko, PE; Verma, S; Wang, CH; Weisel, RD; Zucco, L | 1 |
| Le Feuvre, C | 1 |
| Chiquette, E; Defronzo, R; Ramirez, G | 1 |
| Carey, D; Carr, A; Cooper, DA; Emery, S; Feneley, MP; Kovacic, JC; Mallon, PW; Martin, A; Wand, H | 1 |
| Schumm-Draeger, PM | 1 |
| Os, I | 1 |
| Forst, T; Hamann, A; Matthaei, S; Pfützner, A; Schöndorf, T; Seidel, D; Winkler, K | 1 |
| Edwards, KL; Greene, RS; Irons, BK; Mazzolini, TA; Sleeper, RB | 1 |
| Chu, CS; Lai, WT; Lee, KT; Lee, MY; Sheu, SH; Su, HM; Voon, WC | 1 |
| Esposito, K; Giugliano, D | 1 |
| Andreelli, F; Beauloye, C; Bertrand, L; Foretz, M; Guigas, B; Horman, S; Taleux, N; Viollet, B | 1 |
| Fried, SK; Goldberg, AP; Goldberg, NH; Gong, DW; Horenstein, RB; Hu, H; Hull, K; Lee, MJ; Nicklas, BJ; Pollin, TI; Ryan, AS; Shuldiner, AR; Snitker, S; Yang, RZ | 1 |
| Aguiar, LG; Bahia, L; Bottino, D; Bouskela, E; Godoy-Matos, AF; Villela, N | 1 |
| Cobitz, AR; Goldstein, BJ; Waterhouse, BR; Weissman, PN; Wooddell, MJ | 1 |
| Haffner, SM; Heise, MA; Herman, WH; Holman, RR; Jones, NP; Kahn, SE; Kravitz, BG; Lachin, JM; O'Neill, MC; Viberti, G; Zinman, B | 1 |
| Brunzell, JD; Chen, H; Cobitz, A; Marcovina, SM; Murdoch, SJ; Parikh, SJ; Yu, D | 1 |
| Nissen, SE | 2 |
| Allen, TJ; Calkin, AC; Jandeleit-Dahm, KA; Lassila, M; Thomas, MC; Tikellis, C | 1 |
| Hedner, T; Kjeldsen, SE; Narkiewicz, K; Oparil, S | 1 |
| Furberg, CD; Psaty, BM | 2 |
| Wadman, M | 1 |
| Beck-Nielsen, H; Gomis, R; Hanefeld, M; Home, PD; Jones, NP; Komajda, M; McMurray, JJ; Pocock, SJ | 1 |
| Curfman, GD; Drazen, JM; Morrissey, S | 1 |
| Nathan, DM | 1 |
| Abdel-Latif, A; AlMahameed, A; Bhatt, DL; Blankenship, JC; Brennan, D; Chew, DP; Corbelli, JC; Eres, A; Gilchrist, IC; Grines, C; Hazen, SL; Leesar, M; McErlean, E; Mukherjee, D; Resar, JR; Steinhubl, S; Tan, WA; Tang, HW; Tang, WH; Topol, EJ | 1 |
| Alevizos, M; Angelopoulou, N; Iliadis, F; Kadoglou, NP; Liapis, CD; Perrea, D | 1 |
| Fishman, I; Guttmann, H; Keidar, S; Shapira, C; Stam, T | 1 |
| Bax, L; Diamond, GA; Kaul, S | 1 |
| Avorn, J | 1 |
| Bloomgarden, ZT | 1 |
| Colca, JR | 1 |
| Jenkins, JK; Joffe, HV; Meyer, RJ; Parks, MH; Temple, R | 1 |
| Bracken, MB | 1 |
| Jones, LS; Salmon, DA; Shuster, JJ | 1 |
| Brett, AS | 1 |
| Furberg, CD; Loke, YK; Singh, S | 1 |
| Solomon, DH; Winkelmayer, WC | 1 |
| Lago, RM; Nesto, RW; Singh, PP | 1 |
| Hamilton, PK; Lockhart, CJ; McVeigh, GE; Quinn, CE | 1 |
| Cornell, J; Localio, AR; Mulrow, CD | 1 |
| Hjelmesaeth, J; Røislien, J | 1 |
| Florez, H; Meneghini, LF; Tamariz, L | 1 |
| Boyle, P | 1 |
| Hjelvin, E | 1 |
| Erdmann, E; Hoppe, UC; Michels, G; Rottlaender, D | 1 |
| Eckert, S; Erdmann, E; Forst, T; Lundershausen, R; Scherbaum, WA; Schnell, O; Schumm-Draeger, PM; Standl, E; Tschöpe, D; Walter, H; Weber, M | 1 |
| Atkin, SL; Cho, LW | 1 |
| Demidova, TIu; Erokhina, EN | 1 |
| Mikhail, N | 1 |
| Honisett, SY; Komesaroff, PA; Stojanovska, L | 1 |
| Seidel, D; Strohmeyer, T | 1 |
| Ceska, R; Dobiásová, M; Dolezalová, R; Fait, T; Kasalová, Z; Prázný, M; Stulc, T; Vrablík, M | 1 |
| Goldfine, AB | 1 |
| Berger, JP; Chang, CH; Doebber, TW; McCann, ME; McNamara, LA; Meinke, PT; Muise, ES; Tan, Y; Thompson, JR; Wood, HB; Wu, MS | 1 |
| Kapoor, JR | 1 |
| Dahabreh, IJ; Economopoulos, K | 1 |
| Ceska, R; Stulc, T | 1 |
| Elisaf, MS; Liberopoulos, EN; Mikhailidis, DP; Rizos, CV | 1 |
| Alemao, E; Chen, J; Cook, J; Yin, D | 1 |
| Henry, RR; Mudaliar, S | 1 |
| Daubresse, JC | 1 |
| McMorran, M; Vu, D | 1 |
| Abbasi, F; Chu, JW; Cooke, JP; Lamendola, C; McLaughlin, TL; Reaven, GM; Stühlinger, MC; Tsao, PS | 1 |
| Valensi, P | 1 |
72 review(s) available for rosiglitazone and Cardiovascular Diseases
| Article | Year |
|---|---|
Updating insights into rosiglitazone and cardiovascular risk through shared data: individual patient and summary level meta-analyses.
Topics: Cardiovascular Diseases; Humans; Hypoglycemic Agents; Information Dissemination; Randomized Controlled Trials as Topic; Risk Factors; Rosiglitazone | 2020 |
The Positive Regulation of eNOS Signaling by PPAR Agonists in Cardiovascular Diseases.
Topics: Animals; Cardiovascular Diseases; Glycine; Humans; Nitric Oxide Synthase Type III; Oxazoles; Peroxisome Proliferator-Activated Receptors; Rosiglitazone; Signal Transduction; Thiazolidinediones | 2017 |
PPARs: regulators of metabolism and as therapeutic targets in cardiovascular disease. Part II: PPAR-β/δ and PPAR-γ.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Humans; Metabolic Syndrome; Non-alcoholic Fatty Liver Disease; Pioglitazone; PPAR delta; PPAR gamma; PPAR-beta; Rosiglitazone; Thiazolidinediones | 2017 |
Peroxisome proliferator-activated receptor gamma agonists for preventing recurrent stroke and other vascular events in people with stroke or transient ischaemic attack.
Topics: Cardiovascular Diseases; Carotid Artery Diseases; Humans; Hypoglycemic Agents; Insulin Resistance; Ischemic Attack, Transient; Myocardial Infarction; Pioglitazone; PPAR gamma; Proteasome Endopeptidase Complex; Randomized Controlled Trials as Topic; Recurrence; Rosiglitazone; Secondary Prevention; Stroke; Thiazolidinediones; Ubiquitin | 2017 |
Long-term risk of rosiglitazone on cardiovascular events - a systematic review and meta-analysis.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Male; Patient Safety; Risk; Rosiglitazone | 2018 |
Glucagon-like peptide-1 receptor agonists and cardiovascular protection in type 2 diabetes: a pathophysiology-based review of clinical implications.
Topics: Biomarkers; Blood Glucose; Blood Pressure; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Lipids; Prognosis; Rosiglitazone | 2018 |
Does diabetes prevention translate into reduced long-term vascular complications of diabetes?
Topics: Atherosclerosis; Cardiovascular Diseases; Clinical Trials as Topic; Cost-Benefit Analysis; Diabetes Complications; Diabetes Mellitus, Type 2; Follow-Up Studies; Glucose Intolerance; Humans; Hypoglycemic Agents; Life Style; Metformin; Microcirculation; Preventive Medicine; Ramipril; Risk Factors; Rosiglitazone; Treatment Outcome | 2019 |
Peroxisome proliferator-activated receptor gamma agonists for preventing recurrent stroke and other vascular events in patients with stroke or transient ischaemic attack.
Topics: Cardiovascular Diseases; Humans; Hypoglycemic Agents; Ischemic Attack, Transient; Myocardial Infarction; Pioglitazone; PPAR gamma; Rosiglitazone; Secondary Prevention; Stroke; Thiazolidinediones | 2014 |
Was there really any evidence that rosiglitazone increased the risk of myocardial infarction or death from cardiovascular causes?
Topics: Cardiovascular Diseases; Humans; Hypoglycemic Agents; Mortality; Myocardial Infarction; Randomized Controlled Trials as Topic; Risk Factors; Rosiglitazone; Thiazolidinediones | 2015 |
Pharmacogenomics and pharmacogenetics of thiazolidinediones: role in diabetes and cardiovascular risk factors.
Topics: Cardiovascular Diseases; Chromans; Diabetes Mellitus; Humans; Pharmacogenetics; Pioglitazone; Precision Medicine; Risk Factors; Rosiglitazone; Thiazolidinediones; Troglitazone | 2014 |
Should recent experiences with CVOTs for oral hypoglycemic drugs allow us to rethink the regulatory paradigm?
Topics: Administration, Oral; Cardiovascular Diseases; Clinical Trials as Topic; Humans; Hypoglycemic Agents; Rosiglitazone; Thiazolidinediones; Thinking; United States; United States Food and Drug Administration | 2015 |
Number needed to harm in the post-marketing safety evaluation: results for rosiglitazone and pioglitazone.
Topics: Adverse Drug Reaction Reporting Systems; Cardiovascular Diseases; Female; Humans; Hypoglycemic Agents; Male; Patient Selection; Pioglitazone; Randomized Controlled Trials as Topic; Rosiglitazone; Thiazolidinediones; United States | 2015 |
Peroxisome proliferator-activated receptor gamma agonists for preventing recurrent stroke and other vascular events in patients with stroke or transient ischaemic attack.
Topics: Cardiovascular Diseases; Humans; Hypoglycemic Agents; Ischemic Attack, Transient; Myocardial Infarction; Pioglitazone; PPAR gamma; Randomized Controlled Trials as Topic; Rosiglitazone; Secondary Prevention; Stroke; Thiazolidinediones | 2015 |
Cardiovascular risk associated with the use of glitazones, metformin and sufonylureas: meta-analysis of published observational studies.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Metformin; Myocardial Infarction; Observational Studies as Topic; Pioglitazone; Risk Factors; Rosiglitazone; Stroke; Sulfonylurea Compounds; Thiazolidinediones | 2016 |
Perspectives on Some Controversies in Cardiovascular Disease Risk Assessment in the Pharmaceutical Development of Glucose-Lowering Medications.
Topics: Cardiovascular Diseases; Diabetes Mellitus; Drug Discovery; Drug Evaluation, Preclinical; Drug Industry; Humans; Hypoglycemic Agents; Myocardial Infarction; Risk Assessment; Rosiglitazone; Thiazolidinediones; United States; United States Food and Drug Administration | 2016 |
Challenges in meta-analysis of randomized clinical trials for rare harmful cardiovascular events: the case of rosiglitazone.
Topics: Adverse Drug Reaction Reporting Systems; Cardiovascular Diseases; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Hypoglycemic Agents; Incidence; Male; Meta-Analysis as Topic; Randomized Controlled Trials as Topic; Rare Diseases; Reproducibility of Results; Risk Assessment; Rosiglitazone; Sensitivity and Specificity; Thiazolidinediones | 2008 |
The cardiovascular safety of rosiglitazone.
Topics: Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Meta-Analysis as Topic; Pioglitazone; Risk Factors; Rosiglitazone; Thiazolidinediones | 2008 |
The controversial effects of thiazolidinediones on cardiovascular morbidity and mortality.
Topics: Animals; Cardiovascular Diseases; Cardiovascular System; Edema; Heart Failure; Humans; Pioglitazone; PPAR gamma; Risk Factors; Rosiglitazone; Secondary Prevention; Thiazolidinediones | 2009 |
Pioglitazone and rosiglitazone: effects of treatment with a thiazolidinedione on lipids and non conventional cardiovascular risk factors.
Topics: Adipose Tissue; Apolipoproteins; Atherosclerosis; Cardiovascular Diseases; Dyslipidemias; Humans; Hypoglycemic Agents; Insulin Resistance; Lipids; Peroxisome Proliferator-Activated Receptors; Pioglitazone; Risk Factors; Rosiglitazone; Thiazolidinediones | 2008 |
Rosiglitazone and cardiovascular risk.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Meta-Analysis as Topic; Myocardial Infarction; Pioglitazone; Risk Assessment; Rosiglitazone; Thiazolidinediones | 2008 |
The safety of rosiglitazone in the treatment of type 2 diabetes.
Topics: Blood Glucose; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Fractures, Bone; Heart Failure; Humans; Hypoglycemic Agents; Myocardial Infarction; Risk Factors; Rosiglitazone; Thiazolidinediones | 2008 |
Winners and losers at the rosiglitazone gamble A meta-analytical approach at the definition of the cardiovascular risk profile of rosiglitazone.
Topics: Aged; Body Mass Index; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Heart Failure; Humans; Hypoglycemic Agents; Male; Middle Aged; Myocardial Infarction; Randomized Controlled Trials as Topic; Risk Factors; Rosiglitazone; Thiazolidinediones; Triglycerides | 2008 |
Reassessing the cardiovascular risks and benefits of thiazolidinediones.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin Resistance; Metabolic Syndrome; Pioglitazone; PPAR gamma; Rosiglitazone; Thiazolidinediones | 2008 |
Pharmacological approaches to improve endothelial repair mechanisms.
Topics: AC133 Antigen; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Antigens, CD; Antigens, CD34; Atherosclerosis; Benzopyrans; Carbazoles; Cardiovascular Diseases; Carvedilol; Cell Differentiation; Coronary Disease; Endothelium, Vascular; Erythropoietin; Ethanolamines; Glycoproteins; Hematopoietic Stem Cells; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Insulin; Nebivolol; Neovascularization, Physiologic; Oxidative Stress; Peptides; PPAR gamma; Propanolamines; Receptors, Angiotensin; Regeneration; Risk Factors; Rosiglitazone; Stem Cells; Thiazolidinediones; Vasodilator Agents | 2008 |
Cardiovascular risk of rosiglitazone: another perspective.
Topics: Adverse Drug Reaction Reporting Systems; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Monitoring; Edema; Humans; Hypoglycemic Agents; Patient Selection; Risk Factors; Rosiglitazone; Thiazolidinediones; Weight Gain | 2008 |
Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Selected practical issues in their evaluation and management.
Topics: Bariatric Surgery; Biomarkers; Biopsy; Cardiovascular Diseases; Comorbidity; Diabetes Mellitus, Type 2; Dyslipidemias; Exercise; Fatty Liver; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver; Liver Cirrhosis; Liver Diseases; Metabolic Syndrome; Metformin; Obesity; Oxidative Stress; Pioglitazone; Randomized Controlled Trials as Topic; Rosiglitazone; Thiazolidinediones; Weight Loss | 2009 |
Effects of thiazolidinediones beyond glycaemic control.
Topics: Animals; Blood Glucose; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Peroxisome Proliferator-Activated Receptors; Pioglitazone; Rosiglitazone; Thiazolidinediones | 2009 |
Redefining the role of thiazolidinediones in the management of type 2 diabetes.
Topics: Administration, Oral; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Pioglitazone; Rosiglitazone; Thiazolidinediones; Treatment Outcome | 2009 |
The role of pioglitazone in modifying the atherogenic lipoprotein profile.
Topics: Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Lipoproteins; Pioglitazone; PPAR gamma; Rosiglitazone; Thiazolidinediones; Triglycerides | 2009 |
Cardiovascular disease and type 2 diabetes mellitus: regulating glucose and regulating drugs.
Topics: Anticholesteremic Agents; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemic Agents; Quinolines; Randomized Controlled Trials as Topic; Rosiglitazone; Thiazolidinediones | 2009 |
Lay media reporting of rosiglitazone risk: extent, messaging and quality of reporting.
Topics: Cardiovascular Diseases; Communications Media; Humans; Newspapers as Topic; Rosiglitazone; Thiazolidinediones | 2009 |
Is the evidence from clinical trials for cardiovascular risk or harm for glitazones convincing?
Topics: Cardiovascular Diseases; Clinical Trials as Topic; Humans; Hypoglycemic Agents; Pioglitazone; PPAR gamma; Rosiglitazone; Thiazolidinediones | 2009 |
Different effects of thiazolidinediones on cardiovascular risk in patients with type 2 diabetes mellitus: pioglitazone versus rosiglitazone.
Topics: Animals; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug Delivery Systems; Humans; Hypoglycemic Agents; Insulin Resistance; Pioglitazone; PPAR gamma; Risk Factors; Rosiglitazone; Thiazolidinediones | 2010 |
Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality.
Topics: Biomarkers; Cardiovascular Diseases; Confidence Intervals; Diabetes Mellitus; Europe; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Myocardial Infarction; Odds Ratio; Product Surveillance, Postmarketing; Randomized Controlled Trials as Topic; Registries; Risk Assessment; Risk Factors; Rosiglitazone; Thiazolidinediones; United States; United States Food and Drug Administration | 2010 |
Cardiovascular risk and thiazolidinediones--what do meta-analyses really tell us?
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Humans; Male; Meta-Analysis as Topic; Randomized Controlled Trials as Topic; Risk Factors; Rosiglitazone; Thiazolidinediones | 2010 |
Rosiglitazone and the risk of adverse cardiovascular outcomes.
Topics: Cardiovascular Diseases; Clinical Trials as Topic; Drug and Narcotic Control; Europe; Humans; Medicare; Risk Factors; Rosiglitazone; Thiazolidinediones; Treatment Outcome; United States | 2011 |
Is there clear and convincing evidence of cardiovascular risk with rosiglitazone?
Topics: Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Humans; Meta-Analysis as Topic; Risk Factors; Rosiglitazone; Thiazolidinediones | 2011 |
Recent diabetes issues affecting the primary care clinician.
Topics: Adamantane; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Like Peptide 1; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Incretins; Liraglutide; Metformin; Primary Health Care; Rosiglitazone; Thiazolidinediones; Vitamin B 12 Deficiency | 2011 |
Healing the diabetic heart: modulation of cardiometabolic syndrome through peroxisome proliferator activated receptors (PPARs).
Topics: Biological Products; Cardiovascular Diseases; Glucose; Humans; Hypoglycemic Agents; Ligands; Lipid Metabolism; Peroxisome Proliferator-Activated Receptors; PPAR gamma; Rosiglitazone; Thiazolidinediones | 2012 |
Meta-analysis of incidence of rare events.
Topics: Cardiovascular Diseases; Data Interpretation, Statistical; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Incidence; Meta-Analysis as Topic; Myocardial Infarction; Randomized Controlled Trials as Topic; Research Design; Risk Assessment; Rosiglitazone; Thiazolidinediones | 2013 |
Update on cardiovascular safety of PPARgamma agonists and relevance to medicinal chemistry and clinical pharmacology.
Topics: Animals; Cardiovascular Diseases; Chemistry, Pharmaceutical; Drug-Related Side Effects and Adverse Reactions; Humans; Ligands; Pioglitazone; PPAR gamma; Rosiglitazone; Structure-Activity Relationship; Thiazolidinediones | 2012 |
PPAR agonists for the treatment of cardiovascular disease in patients with diabetes.
Topics: Blood Glucose; Cardiovascular Diseases; Clinical Trials, Phase II as Topic; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Dyslipidemias; Humans; Hypoglycemic Agents; Oxazoles; Peroxisome Proliferator-Activated Receptors; PPAR alpha; PPAR gamma; Rosiglitazone; Thiazolidinediones; Thiophenes; Treatment Outcome | 2012 |
Cardiovascular disease and oral agent glucose-lowering therapies in the management of type 2 diabetes.
Topics: Administration, Oral; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Dipeptidyl-Peptidase IV Inhibitors; Female; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Myocardial Infarction; Randomized Controlled Trials as Topic; Risk Reduction Behavior; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones; United Kingdom | 2012 |
Risk of cardiovascular disease and all-cause mortality among diabetic patients prescribed rosiglitazone or pioglitazone: a meta-analysis of retrospective cohort studies.
Topics: Cardiovascular Diseases; Diabetes Mellitus; Humans; Hypoglycemic Agents; Pioglitazone; Retrospective Studies; Rosiglitazone; Thiazolidinediones | 2012 |
Thiazolidinediones in type 2 diabetes mellitus: current clinical evidence.
Topics: Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones | 2003 |
Pre-diabetes, insulin resistance, inflammation and CVD risk.
Topics: Age Factors; Biomarkers; C-Reactive Protein; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Disease Progression; Humans; Inflammation; Insulin Resistance; Prediabetic State; Risk Factors; Rosiglitazone; Sex Factors; Thiazolidinediones | 2003 |
Type 2 diabetes, cardiovascular risk, and the link to insulin resistance.
Topics: Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Type 2; Hemodynamics; Humans; Hyperlipidemias; Hypoglycemic Agents; Insulin Resistance; Obesity; Pioglitazone; Risk Factors; Rosiglitazone; Thiazolidinediones | 2003 |
Effects of the thiazolidinediones on cardiovascular risk factors.
Topics: Cardiovascular Diseases; Chromans; Clinical Trials as Topic; Endothelium, Vascular; Humans; Hypoglycemic Agents; Insulin Resistance; Pioglitazone; Risk Factors; Rosiglitazone; Thiazolidinediones; Troglitazone | 2002 |
[Cardiovascular effects of rosiglitazone].
Topics: Cardiovascular Diseases; Cardiovascular System; Cause of Death; Diabetes Mellitus, Type 2; Drug Monitoring; Edema; France; Heart Failure; Humans; Hypoglycemic Agents; Inflammation; Insulin Resistance; Morbidity; Primary Prevention; Research Design; Risk Factors; Rosiglitazone; Thiazolidinediones; Treatment Outcome; Vasodilator Agents | 2004 |
A meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factors.
Topics: Blood Glucose; Blood Pressure; Body Weight; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Lipids; Middle Aged; Pioglitazone; Randomized Controlled Trials as Topic; Risk Factors; Rosiglitazone; Thiazolidinediones; Treatment Outcome | 2004 |
[Glucose-independent impact of the glitazones on the cardiovascular outcome].
Topics: Body Mass Index; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Insulin Resistance; Longitudinal Studies; Middle Aged; Obesity; Pioglitazone; Primary Prevention; Prospective Studies; Randomized Controlled Trials as Topic; Risk Factors; Rosiglitazone; Thiazolidinediones | 2005 |
[Controversial therapeutic strategies in the treatment of type 2 diabetes mellitus].
Topics: Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Follow-Up Studies; Gliclazide; Humans; Hypoglycemic Agents; Insulin Resistance; Metformin; Pioglitazone; Risk Factors; Rosiglitazone; Thiazolidinediones; Time Factors | 2005 |
Implications of rosiglitazone and pioglitazone on cardiovascular risk in patients with type 2 diabetes mellitus.
Topics: Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus, Type 2; Heart Failure; Humans; Hypoglycemic Agents; Pioglitazone; Risk Assessment; Rosiglitazone; Thiazolidinediones; Treatment Outcome | 2006 |
[Regulation of energy metabolism by AMPK: a novel therapeutic approach for the treatment of metabolic and cardiovascular diseases].
Topics: Adenosine Monophosphate; Adenosine Triphosphate; Adipogenesis; Allosteric Regulation; AMP-Activated Protein Kinases; Animals; Cardiovascular Diseases; Cholesterol; Diabetes Mellitus, Type 2; Drug Design; Energy Intake; Energy Metabolism; Enzyme Activation; Fatty Acids; Glucose; Homeostasis; Humans; Hypothalamus; Lipogenesis; Mammals; Metformin; Models, Biological; Multienzyme Complexes; Myocardium; Obesity; Phosphorylation; Protein Processing, Post-Translational; Protein Serine-Threonine Kinases; Protein Structure, Tertiary; Protein Subunits; Rosiglitazone; Thiazolidinediones | 2006 |
The question of whether diabetes and its cardiovascular risks can be prevented: a realistic DREAM?
Topics: Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus; Diabetic Angiopathies; Humans; Premedication; Ramipril; Rosiglitazone; Thiazolidinediones; Treatment Outcome | 2006 |
Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Middle Aged; Myocardial Infarction; Odds Ratio; Randomized Controlled Trials as Topic; Risk Assessment; Rosiglitazone; Thiazolidinediones | 2007 |
Cardiovascular benefits and safety profile of acarbose therapy in prediabetes and established type 2 diabetes.
Topics: Acarbose; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Humans; Hypertension; Hypoglycemic Agents; Metformin; Prediabetic State; Rosiglitazone; Safety; Thiazolidinediones | 2007 |
Future directions for insulin sensitizers in disease prevention.
Topics: Animals; Anti-Inflammatory Agents; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug Design; Humans; Hypoglycemic Agents; Mice; Mice, Knockout; Pioglitazone; PPAR gamma; Rosiglitazone; Thiazolidinediones; Treatment Outcome | 2007 |
Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis.
Topics: Cardiac Output, Low; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Myocardial Infarction; Randomized Controlled Trials as Topic; Risk; Rosiglitazone; Thiazolidinediones | 2007 |
Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials.
Topics: Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus, Type 2; Female; Heart Failure; Humans; Hypoglycemic Agents; Male; Middle Aged; Pioglitazone; Randomized Controlled Trials as Topic; Risk Factors; Rosiglitazone; Thiazolidinediones | 2007 |
Thiazolidinediones: effects on insulin resistance and the cardiovascular system.
Topics: Adipokines; Animals; Atherosclerosis; Cardiovascular Diseases; Cardiovascular System; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin Resistance; PPAR alpha; PPAR gamma; Risk Assessment; Risk Factors; Rosiglitazone; Thiazolidinediones; Treatment Outcome | 2008 |
[Therapy with glitazones--a risk for cardiovascular disease?].
Topics: Cardiovascular Diseases; Cholesterol, LDL; Contraindications; Diabetes Mellitus, Type 2; Dyslipidemias; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Resistance; Pioglitazone; Risk Assessment; Risk Factors; Rosiglitazone; Thiazolidinediones | 2007 |
Rosiglitazone and cardiovascular risk: weighing recent evidence.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Randomized Controlled Trials as Topic; Rosiglitazone; Thiazolidinediones | 2007 |
Cardiovascular risk in women with polycystic ovary syndrome.
Topics: Atherosclerosis; Biomarkers; Body Weight; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Exercise; Female; Humans; Hypoglycemic Agents; Metformin; Pioglitazone; Polycystic Ovary Syndrome; Risk Factors; Risk Reduction Behavior; Rosiglitazone; Thiazolidinediones; Vasodilator Agents; Weight Loss | 2007 |
The anti-atherogenic effects of thiazolidinediones.
Topics: Atherosclerosis; Biomarkers; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Endothelium, Vascular; Humans; Hypolipidemic Agents; Kidney; Lipid Metabolism; Models, Biological; Pioglitazone; Postmenopause; Rosiglitazone; Thiazolidinediones | 2007 |
The rough road for rosiglitazone.
Topics: Cardiovascular Diseases; Diabetes Mellitus; Heart Failure; Humans; Hypoglycemic Agents; Meta-Analysis as Topic; Risk Factors; Rosiglitazone; Thiazolidinediones; Time Factors | 2008 |
Meta-analysis of rare events: an update and sensitivity analysis of cardiovascular events in randomized trials of rosiglitazone.
Topics: Cardiovascular Diseases; Heart Failure; Humans; Hypoglycemic Agents; Myocardial Infarction; Randomized Controlled Trials as Topic; Risk Factors; Rosiglitazone; Thiazolidinediones | 2008 |
Rosiglitazone in the prevention of diabetes and cardiovascular disease: dream or reality?
Topics: Cardiovascular Diseases; Diabetes Mellitus; Humans; PPAR gamma; Risk Factors; Rosiglitazone; Thiazolidinediones | 2008 |
Pleiotropic effects of thiazolidinediones.
Topics: Atherosclerosis; Body Fat Distribution; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Pioglitazone; Risk Factors; Rosiglitazone; Thiazolidinediones | 2008 |
New oral therapies for type 2 diabetes mellitus: The glitazones or insulin sensitizers.
Topics: Cardiovascular Diseases; Chromans; Diabetes Mellitus, Type 2; Drug Interactions; Humans; Hypoglycemic Agents; Insulin Resistance; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones; Treatment Outcome; Troglitazone | 2001 |
[The importance of syndrome X in daily practice].
Topics: Anthropometry; Cardiovascular Diseases; Diet, Reducing; Exercise; Humans; Hyperinsulinism; Hypertension; Hypertriglyceridemia; Hypoglycemic Agents; Insulin Resistance; Lipoproteins, HDL; Lipoproteins, LDL; Obesity; Rosiglitazone; Thiazoles; Thiazolidinediones | 2000 |
[Rosiglitazone: a clinical development focused on cardio-vascular prevention].
Topics: Albuminuria; Animals; Blood Pressure; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Endothelium, Vascular; Humans; Hypoglycemic Agents; Plasminogen Activator Inhibitor 1; Risk Factors; Rosiglitazone; Thiazoles; Thiazolidinediones | 2002 |
30 trial(s) available for rosiglitazone and Cardiovascular Diseases
| Article | Year |
|---|---|
Cardiac Biomarkers in Youth with Type 2 Diabetes Mellitus: Results from the TODAY Study.
Topics: Adolescent; Biomarkers; Cardiovascular Diseases; Child; Combined Modality Therapy; Diabetes Mellitus, Type 2; Diet Therapy; Drug Therapy, Combination; Echocardiography; Exercise Therapy; Female; Follow-Up Studies; Heart Ventricles; Humans; Hypoglycemic Agents; Male; Metformin; Risk Factors; Rosiglitazone; Thiazolidinediones; Treatment Outcome; Ventricular Function, Left | 2018 |
The effect of intensive glucose lowering on lipoprotein particle profiles and inflammatory markers in the Veterans Affairs Diabetes Trial (VADT).
Topics: Biomarkers; Blood Glucose; Cardiovascular Diseases; Cholesterol; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Interleukin-6; Lipoproteins; Male; Metformin; Middle Aged; Risk Factors; Rosiglitazone; Thiazolidinediones | 2013 |
Tissue factor expression in obese type 2 diabetic subjects and its regulation by antidiabetic agents.
Topics: Adult; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Gene Expression Regulation; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Obesity; Rosiglitazone; Thiazolidinediones; Thromboplastin | 2015 |
Rosiglitazone treatment and cardiovascular disease in the Veterans Affairs Diabetes Trial.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Male; Middle Aged; Myocardial Infarction; Propensity Score; Proportional Hazards Models; Risk Factors; Rosiglitazone; Thiazolidinediones; Time Factors; United States; United States Department of Veterans Affairs | 2015 |
Comparison of three treatment approaches to decreasing cardiovascular disease risk in nondiabetic insulin-resistant dyslipidemic subjects.
Topics: Adult; Aged; Blood Glucose; Caloric Restriction; Cardiovascular Diseases; Cholesterol; Dyslipidemias; Fatty Acids, Nonesterified; Female; Fenofibrate; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Insulin Resistance; Lipoproteins; Male; Middle Aged; Risk Factors; Rosiglitazone; Thiazolidinediones; Triglycerides | 2008 |
Improvement of endothelial function with metformin and rosiglitazone treatment in women with polycystic ovary syndrome.
Topics: Androgens; Brachial Artery; C-Reactive Protein; Cardiovascular Diseases; Endothelium, Vascular; Female; Homeostasis; Humans; Hypoglycemic Agents; Insulin Resistance; Lipids; Menstrual Cycle; Metformin; Polycystic Ovary Syndrome; Rosiglitazone; Thiazolidinediones; Vasodilation | 2008 |
Glucose control and vascular complications in veterans with type 2 diabetes.
Topics: Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Neuropathies; Drug Therapy, Combination; Female; Follow-Up Studies; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Kaplan-Meier Estimate; Male; Metformin; Middle Aged; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones; United States; Veterans | 2009 |
The effect of rosiglitazone on integrated cardiovascular performance, cardiac structure, function and myocardial triglyceride: trial design and rationale.
Topics: Adult; Cardiovascular Diseases; Cardiovascular Physiological Phenomena; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Exercise Test; Fibrinolytic Agents; Heart; Humans; Hypoglycemic Agents; Myocardium; Oxygen Consumption; Reproducibility of Results; Research Design; Rosiglitazone; Thiazolidinediones; Triglycerides; Young Adult | 2009 |
Exercise training ameliorates the effects of rosiglitazone on traditional and novel cardiovascular risk factors in patients with type 2 diabetes mellitus.
Topics: Aged; Body Composition; C-Reactive Protein; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Exercise; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Resistance; Lipoproteins, LDL; Male; Middle Aged; Risk Factors; Rosiglitazone; Thiazolidinediones | 2010 |
Pharmacodynamic effects of rosiglitazone in nondiabetic patients with metabolic syndrome.
Topics: Adiponectin; Adult; Biomarkers; Blood Glucose; Blood Pressure; Body Weight; Cardiovascular Diseases; Double-Blind Method; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Lipids; Lipoproteins; Male; Metabolic Syndrome; Middle Aged; Resistin; Rosiglitazone; Thiazolidinediones; Time Factors; Waist Circumference | 2010 |
Carotid intima media thickness, inflammatory markers, and endothelial activation markers in HIV Patients with lipoatrophy increased at 48 weeks regardless of use of rosiglitazone or placebo.
Topics: Adult; Anti-Retroviral Agents; Biomarkers; Cardiovascular Diseases; Carotid Artery, Common; Cholesterol; Cytokines; Diabetes Mellitus; Endothelium, Vascular; Extremities; Female; HIV Infections; Humans; Inflammation; Lipodystrophy; Male; Middle Aged; Rosiglitazone; Thiazolidinediones; Tunica Intima | 2011 |
Drospirenone/ethinyl estradiol versus rosiglitazone treatment in overweight adolescents with polycystic ovary syndrome: comparison of metabolic, hormonal, and cardiovascular risk factors.
Topics: Adolescent; Adrenocorticotropic Hormone; Androstenes; Body Composition; Cardiovascular Diseases; Double-Blind Method; Ethinyl Estradiol; Female; Glucose Clamp Technique; Glucose Tolerance Test; Hemodynamics; Hormones; Humans; Hyperandrogenism; Hypoglycemic Agents; Insulin Resistance; Menstrual Cycle; Mineralocorticoid Receptor Antagonists; Overweight; Polycystic Ovary Syndrome; Risk Factors; Rosiglitazone; Stimulation, Chemical; Thiazolidinediones | 2011 |
The effects of rosiglitazone and metformin on inflammation and endothelial dysfunction in patients with type 2 diabetes mellitus.
Topics: Adult; C-Peptide; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Endothelial Cells; Female; Humans; Interleukin-6; Male; Metformin; Middle Aged; Rosiglitazone; Thiazolidinediones; Tumor Necrosis Factor-alpha | 2011 |
Rosiglitazone decreases plasma levels of osteoprotegerin in a randomized clinical trial with type 2 diabetes patients.
Topics: Adult; Aged; Biomarkers; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Osteoprotegerin; Rosiglitazone; Thiazolidinediones; Treatment Outcome | 2011 |
Design, history and results of the Thiazolidinedione Intervention with vitamin D Evaluation (TIDE) randomised controlled trial.
Topics: Aged; Cardiovascular Diseases; Cholecalciferol; Combined Modality Therapy; Diabetes Mellitus, Type 2; Dietary Supplements; Dose-Response Relationship, Drug; Double-Blind Method; Early Termination of Clinical Trials; Female; Humans; Hypoglycemic Agents; Incidence; Male; Middle Aged; Neoplasms; Pioglitazone; Risk Factors; Rosiglitazone; Thiazolidinediones | 2012 |
Serum A-FABP is increased and closely associated with elevated NT-proBNP levels in type 2 diabetic patients treated with rosiglitazone.
Topics: Adult; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Fatty Acid-Binding Proteins; Female; Humans; Hypoglycemic Agents; Male; Middle Aged; Natriuretic Peptide, Brain; Peptide Fragments; Receptor Cross-Talk; Rosiglitazone; Thiazolidinediones | 2011 |
A comparison of the effect of glitazones on serum sialic acid in patients with type 2 diabetes.
Topics: Biomarkers; Blood Glucose; Cardiovascular Diseases; Cholesterol; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; N-Acetylneuraminic Acid; Pioglitazone; Rosiglitazone; Thiazolidinediones; Treatment Outcome | 2012 |
The effects of rosiglitazone on myocardial triglyceride content in patients with type 2 diabetes: a randomised, placebo-controlled trial.
Topics: Aged; Cardiovascular Diseases; Chi-Square Distribution; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Humans; Hypoglycemic Agents; Linear Models; Magnetic Resonance Imaging; Magnetic Resonance Spectroscopy; Male; Middle Aged; Myocardium; Placebos; Prevalence; Prospective Studies; Risk Assessment; Risk Factors; Rosiglitazone; Stroke Volume; Texas; Thiazolidinediones; Time Factors; Treatment Outcome; Triglycerides; Ventricular Function, Left | 2012 |
Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus.
Topics: Biomarkers; Body Weight; C-Reactive Protein; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Double-Blind Method; Female; Humans; Interleukin-6; Leukocyte Count; Male; Matrix Metalloproteinase 9; Middle Aged; Receptors, Cytoplasmic and Nuclear; Risk Factors; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors | 2002 |
Influence of rosiglitazone on flow-mediated dilation and other markers of cardiovascular risk in HIV-infected patients with lipoatrophy.
Topics: Adult; Anti-HIV Agents; Australia; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Double-Blind Method; Female; HIV Infections; HIV-Associated Lipodystrophy Syndrome; Humans; Insulin Resistance; Male; Middle Aged; Risk Factors; Rosiglitazone; Thiazolidinediones; Vasodilation | 2005 |
Impact of rosiglitazone on beta-cell function, insulin resistance, and adiponectin concentrations: results from a double-blind oral combination study with glimepiride.
Topics: Adiponectin; Aged; C-Reactive Protein; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Combinations; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Insulin-Secreting Cells; Male; Middle Aged; Pancreatic Function Tests; Proinsulin; Prospective Studies; Risk Factors; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones | 2006 |
Effects of rosiglitazone alone and in combination with atorvastatin on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus.
Topics: Adiponectin; Aged; Anticholesteremic Agents; Atorvastatin; Biomarkers; C-Reactive Protein; Cardiovascular Diseases; CD40 Ligand; Cholesterol, LDL; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Enzyme-Linked Immunosorbent Assay; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Male; Matrix Metalloproteinase 9; Middle Aged; Pyrroles; Rosiglitazone; Thiazolidinediones; Treatment Outcome; Triglycerides; Vasodilator Agents | 2006 |
Reductions in biomarkers of cardiovascular risk in type 2 diabetes with rosiglitazone added to metformin compared with dose escalation of metformin: an EMPIRE trial sub-study.
Topics: Adolescent; Adult; Aged; Biomarkers; Blood Glucose; C-Reactive Protein; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Resistance; Male; Matrix Metalloproteinase 9; Metformin; Middle Aged; Plasminogen Activator Inhibitor 1; Rosiglitazone; Thiazolidinediones; Tumor Necrosis Factor-alpha | 2006 |
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy.
Topics: Cardiovascular Diseases; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glyburide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Kaplan-Meier Estimate; Male; Metformin; Middle Aged; Proportional Hazards Models; Rosiglitazone; Thiazolidinediones; Treatment Outcome; Waist-Hip Ratio; Weight Gain | 2006 |
Rosiglitazone increases LDL particle size and buoyancy and decreases C-reactive protein in patients with type 2 diabetes on statin therapy.
Topics: Blood Glucose; C-Reactive Protein; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Insulin Resistance; Lipoproteins, LDL; Male; Middle Aged; Particle Size; Plasminogen Activator Inhibitor 1; Rosiglitazone; Thiazolidinediones; Treatment Outcome | 2006 |
Rosiglitazone evaluated for cardiovascular outcomes--an interim analysis.
Topics: Adult; Aged; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Follow-Up Studies; Heart Failure; Hospitalization; Humans; Hypoglycemic Agents; Kaplan-Meier Estimate; Male; Metformin; Middle Aged; Myocardial Infarction; Risk; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones | 2007 |
Peroxisome proliferator-activated receptor gamma agonists for the Prevention of Adverse events following percutaneous coronary Revascularization--results of the PPAR study.
Topics: Angioplasty, Balloon, Coronary; Biomarkers; Cardiovascular Diseases; Coronary Disease; Disease Progression; Double-Blind Method; Female; Humans; Hypoglycemic Agents; Male; Metabolic Syndrome; Middle Aged; Natriuretic Peptide, Brain; Pilot Projects; PPAR gamma; Rosiglitazone; Thiazolidinediones | 2007 |
Beneficial effects of combined treatment with rosiglitazone and exercise on cardiovascular risk factors in patients with type 2 diabetes.
Topics: Aged; Cardiovascular Diseases; Combined Modality Therapy; Diabetes Mellitus, Type 2; Exercise Therapy; Female; Humans; Hypoglycemic Agents; Male; Middle Aged; Obesity; Risk Factors; Rosiglitazone; Thiazolidinediones | 2007 |
[Metabolic and hemodynamic effects of combined treatment with metformine and rosiglitasone (avandium) in patients with diabetes mellitus type 2 and high cardiovascular risk].
Topics: Adipose Tissue; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Body Mass Index; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Hemodynamics; Humans; Hypertension; Hypoglycemic Agents; Lipid Metabolism; Male; Metformin; Middle Aged; Risk Factors; Rosiglitazone; Thiazolidinediones | 2007 |
Fenofibrate and rosiglitazone improve quality of lipoproteins in patients with type 2 diabetes mellitus.
Topics: Aged; Biomarkers; Cardiovascular Diseases; Cholesterol, LDL; Diabetes Mellitus, Type 2; Female; Fenofibrate; Humans; Lipoproteins; Male; Middle Aged; Peroxisome Proliferator-Activated Receptors; Phosphatidylcholine-Sterol O-Acyltransferase; Predictive Value of Tests; Risk Factors; Rosiglitazone; Thiazolidinediones | 2008 |
120 other study(ies) available for rosiglitazone and Cardiovascular Diseases
| Article | Year |
|---|---|
No causal effects between rosiglitazone and cardiovascular disease or risk factors: a Mendelian randomization study.
Topics: Cardiovascular Diseases; Genome-Wide Association Study; Humans; Mendelian Randomization Analysis; Polymorphism, Single Nucleotide; Risk Factors; Rosiglitazone | 2023 |
Impact of Regulatory Guidance on Evaluating Cardiovascular Risk of New Glucose-Lowering Therapies to Treat Type 2 Diabetes Mellitus: Lessons Learned and Future Directions.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug-Related Side Effects and Adverse Reactions; Glucose; Glycated Hemoglobin; Glycine; Government Regulation; Humans; Hypoglycemic Agents; Oxazoles; Phenylbutazone; Practice Guidelines as Topic; Risk; Rosiglitazone; Tolbutamide; United States; United States Food and Drug Administration | 2020 |
ERK1/2-PPARγ pathway is involved in
Topics: Apoptosis; Atherosclerosis; Cardiovascular Diseases; Cell Proliferation; Chlamydophila pneumoniae; Gene Expression Regulation; Human Umbilical Vein Endothelial Cells; Humans; MAP Kinase Signaling System; p38 Mitogen-Activated Protein Kinases; PPAR gamma; Rosiglitazone; Scavenger Receptors, Class E; Signal Transduction; Umbilical Veins | 2020 |
The perils of data sharing, meta-analyses, and estimating cardiovascular risk.
Topics: Cardiovascular Diseases; Heart Disease Risk Factors; Humans; Information Dissemination; Risk Factors; Rosiglitazone | 2021 |
The cardiovascular safety of diabetes drugs--insights from the rosiglitazone experience.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug Approval; Europe; Humans; Hypoglycemic Agents; Myocardial Infarction; Rosiglitazone; Safety-Based Drug Withdrawals; Thiazolidinediones; United States; United States Food and Drug Administration | 2013 |
Objective Bayesian meta-analysis for sparse discrete data.
Topics: Bayes Theorem; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestational; Epilepsy; Female; gamma-Aminobutyric Acid; Hormone Replacement Therapy; Humans; Meta-Analysis as Topic; Models, Statistical; Multicenter Studies as Topic; Pregnancy; Rosiglitazone; Thiazolidinediones; Treatment Outcome | 2014 |
The Yin and the Yang of CV risks in patients with diabetes.
Topics: Adamantane; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptides; Drug-Related Side Effects and Adverse Reactions; Heart Failure; Heart Rate; Humans; Hypoglycemia; Hypoglycemic Agents; Incretins; Myocardial Infarction; Pioglitazone; Risk Assessment; Rosiglitazone; Safety-Based Drug Withdrawals; Stroke; Thiazolidinediones; United States; United States Food and Drug Administration | 2014 |
How Did Multiple FDA Actions Affect the Utilization and Reimbursed Costs of Thiazolidinediones in US Medicaid?
Topics: Cardiovascular Diseases; Costs and Cost Analysis; Diabetes Mellitus, Type 2; Drug Utilization; Humans; Hypoglycemic Agents; Medicaid; Pioglitazone; Reimbursement Mechanisms; Risk Factors; Rosiglitazone; Thiazolidinediones; United States; United States Food and Drug Administration | 2015 |
Targeted Proteomics Identifies Paraoxonase/Arylesterase 1 (PON1) and Apolipoprotein Cs as Potential Risk Factors for Hypoalphalipoproteinemia in Diabetic Subjects Treated with Fenofibrate and Rosiglitazone.
Topics: Aged; Apolipoprotein C-II; Aryldialkylphosphatase; Cardiovascular Diseases; Case-Control Studies; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Fenofibrate; Humans; Hypoalphalipoproteinemias; Hypoglycemic Agents; Hypolipidemic Agents; Lipoproteins, HDL; Male; Middle Aged; Proteomics; Risk Factors; Rosiglitazone; Thiazolidinediones | 2016 |
Low-event-rate meta-analyses of clinical trials: implementing good practices.
Topics: Biostatistics; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Meta-Analysis as Topic; Models, Statistical; Risk; Risk Factors; Rosiglitazone; Thiazolidinediones | 2016 |
Comparative cost-effectiveness of metformin-based dual therapies associated with risk of cardiovascular diseases among Chinese patients with type 2 diabetes: Evidence from a population-based national cohort in Taiwan.
Topics: Acarbose; Aged; Cardiovascular Diseases; Cost-Benefit Analysis; Diabetes Complications; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Male; Markov Chains; Metformin; Middle Aged; Pioglitazone; Risk; Rosiglitazone; Sulfonylurea Compounds; Taiwan; Thiazolidinediones | 2016 |
Meta-analysis of aggregate data on medical events.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Likelihood Functions; Meta-Analysis as Topic; Models, Statistical; Patient Dropouts; Randomized Controlled Trials as Topic; Rosiglitazone; Statistics as Topic; Thiazolidinediones; Time Factors | 2017 |
Transcriptome alteration in the diabetic heart by rosiglitazone: implications for cardiovascular mortality.
Topics: Animals; Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Disease Models, Animal; Echocardiography; Gene Expression Profiling; Insulin; Magnetic Resonance Imaging; Mice; Mice, Inbred C57BL; Mice, Transgenic; Myocardium; Rosiglitazone; Thiazolidinediones | 2008 |
Effect of folic acid and B vitamins on cardiovascular disease in women.
Topics: Adult; Cardiovascular Diseases; Dietary Supplements; Female; Folic Acid; Humans; Hypoglycemic Agents; Risk Factors; Rosiglitazone; Thiazolidinediones; Vitamin B Complex | 2008 |
Intensive glucose control in type 2 diabetes.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Rosiglitazone; Thiazolidinediones | 2008 |
Exact and efficient inference procedure for meta-analysis and its application to the analysis of independent 2 x 2 tables with all available data but without artificial continuity correction.
Topics: Cardiovascular Diseases; Clinical Trials as Topic; Data Interpretation, Statistical; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Meta-Analysis as Topic; Numerical Analysis, Computer-Assisted; Rosiglitazone; Thiazolidinediones | 2009 |
Relationship between changes in insulin sensitivity and associated cardiovascular disease risk factors in thiazolidinedione-treated, insulin-resistant, nondiabetic individuals: pioglitazone versus rosiglitazone.
Topics: Blood Glucose; Body Mass Index; Cardiovascular Diseases; Cholesterol; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Male; Middle Aged; Overweight; Pioglitazone; Risk Factors; Rosiglitazone; Thiazolidinediones | 2009 |
Response to "Rosiglitazone no longer recommended".
Topics: Cardiovascular Diseases; Drug-Related Side Effects and Adverse Reactions; Humans; Hypoglycemic Agents; Randomized Controlled Trials as Topic; Reproducibility of Results; Rosiglitazone; Thiazolidinediones | 2009 |
Relationship between thiazolidinedione use and cardiovascular outcomes and all-cause mortality among patients with diabetes: a time-updated propensity analysis.
Topics: Acute Disease; Cardiovascular Diseases; Cohort Studies; Data Interpretation, Statistical; Diabetes Mellitus, Type 2; Disease Progression; Drug Therapy, Combination; Female; Hospitalization; Humans; Hypoglycemic Agents; Male; Middle Aged; Myocardial Infarction; Pioglitazone; Proportional Hazards Models; Retrospective Studies; Rosiglitazone; Stroke; Thiazolidinediones; Treatment Outcome | 2009 |
In vitro and in vivo assessment of the effect of dalcetrapib on a panel of CYP substrates.
Topics: Adolescent; Adult; Aged; Amides; Aryl Hydrocarbon Hydroxylases; Cardiovascular Diseases; Clinical Trials, Phase II as Topic; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP2C8; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Drug Therapy, Combination; Enzyme Inhibitors; Esters; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Microsomes, Liver; Middle Aged; Rosiglitazone; Sulfhydryl Compounds; Thiazolidinediones; Young Adult | 2009 |
GlaxoSmithKline responds to the consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes.
Topics: Algorithms; Cardiovascular Diseases; Consensus Development Conferences as Topic; Controlled Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Industry; Europe; Humans; Hypoglycemic Agents; Rosiglitazone; Societies, Medical; Thiazolidinediones; United States | 2009 |
Rosiglitazone is associated with mortality in chronic hemodialysis patients.
Topics: Aged; Cardiovascular Diseases; Diabetic Angiopathies; Diabetic Nephropathies; Female; Hospitalization; Humans; Hypoglycemic Agents; Kidney Failure, Chronic; Male; Middle Aged; Proportional Hazards Models; Renal Dialysis; Rosiglitazone; Thiazolidinediones | 2009 |
Clinical and demographic characteristics of patients receiving different oral hypoglycemic agents.
Topics: Administration, Oral; Age Factors; Aged; Aged, 80 and over; Cardiovascular Diseases; Comorbidity; Consumer Product Safety; Diabetes Mellitus; Female; Humans; Hypoglycemic Agents; Male; Ontario; Pioglitazone; Registries; Risk Assessment; Risk Factors; Rosiglitazone; Thiazolidinediones | 2009 |
Glucose control and vascular complications in type 2 diabetes.
Topics: Blood Glucose; Cardiovascular Diseases; Confounding Factors, Epidemiologic; Diabetes Mellitus, Type 2; Dyspnea; Humans; Hypoglycemic Agents; Rosiglitazone; Thiazolidinediones | 2009 |
Thiazolidinediones and the influence of media adverse reporting on prescribing attitudes in practice (TZD-IMPACT) study.
Topics: Attitude of Health Personnel; Awareness; Cardiovascular Diseases; Consumer Product Safety; Diabetes Mellitus, Type 2; Drug Information Services; Evidence-Based Medicine; Health Care Surveys; Health Knowledge, Attitudes, Practice; Humans; Hypoglycemic Agents; Mass Media; Meta-Analysis as Topic; Pioglitazone; Practice Patterns, Physicians'; Risk Assessment; Rosiglitazone; Scotland; Surveys and Questionnaires; Thiazolidinediones; Time Factors | 2009 |
Rosiglitazone.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Europe; Humans; Hypoglycemic Agents; Meta-Analysis as Topic; Rosiglitazone; Societies, Medical; Thiazolidinediones; United States | 2009 |
Cardiovascular risk and TZD: safe therapy for the elderly?
Topics: Age Factors; Aged; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Pioglitazone; Risk Factors; Rosiglitazone; Thiazolidinediones | 2009 |
Thiazolidinediones and cardiovascular events in patients with type 2 diabetes mellitus: a retrospective cohort study of over 473,000 patients using the National Health Insurance database in Taiwan.
Topics: Aged; Cardiovascular Diseases; Cohort Studies; Databases, Factual; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pioglitazone; Proportional Hazards Models; Retrospective Studies; Rosiglitazone; Sulfonylurea Compounds; Taiwan; Thiazolidinediones | 2009 |
[Rosiglitazone: no increase in cardiovascular mortality].
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Follow-Up Studies; Humans; Hypoglycemic Agents; Myocardial Infarction; Rosiglitazone; Thiazolidinediones | 2009 |
Drug therapies for the primary prevention of cardiovascular events: trials and errors: 2009 Ancel Keys Memorial Lecture.
Topics: Cardiovascular Diseases; Cholesterol; Clinical Trials as Topic; Comparative Effectiveness Research; Humans; Risk Assessment; Rosiglitazone; Thiazolidinediones | 2010 |
A perspective on the American Heart Association/American College of Cardiology science advisory on thiazolidinedione drugs and cardiovascular risks.
Topics: Advisory Committees; American Heart Association; Cardiovascular Diseases; Contraindications; Diabetes Mellitus, Type 2; Evidence-Based Medicine; Humans; Hypoglycemic Agents; Pioglitazone; Practice Guidelines as Topic; Rosiglitazone; Thiazolidinediones; United States | 2010 |
Thiazolidinedione drugs and cardiovascular risks: a science advisory from the American Heart Association and American College Of Cardiology Foundation.
Topics: American Heart Association; Cardiology; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Heart Failure; Humans; Hypoglycemic Agents; Myocardial Ischemia; Pioglitazone; Rosiglitazone; Societies, Medical; Thiazolidinediones; United States | 2010 |
Rosiglitazone reverses cardiac adverse remodeling (fibrosis and vascularization) in perinatal low protein rat offspring.
Topics: Animals; Blood Pressure; Cardiovascular Diseases; Diet, Protein-Restricted; Fibrosis; Heart; Hypoglycemic Agents; Male; PPAR gamma; Rats; Rats, Wistar; Rosiglitazone; Thiazolidinediones; Ventricular Remodeling | 2010 |
GSK is accused of trying to suppress editorial on rosiglitazone.
Topics: Cardiovascular Diseases; Drug Industry; Humans; Hypoglycemic Agents; Periodicals as Topic; Publishing; Rosiglitazone; Thiazolidinediones; Truth Disclosure | 2010 |
Database evaluation of the effects of long-term rosiglitazone treatment on cardiovascular outcomes in patients with type 2 diabetes.
Topics: Aged; Cardiovascular Diseases; Databases, Factual; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Heart Failure; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Retrospective Studies; Rosiglitazone; Thiazolidinediones | 2011 |
Diabetes: making sense of the rosiglitazone controversy.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Evidence-Based Medicine; Humans; Hypoglycemic Agents; Patient Selection; Risk Assessment; Risk Factors; Rosiglitazone; Thiazolidinediones; Treatment Outcome | 2010 |
Thiazolidinediones, cardiovascular disease and cardiovascular mortality: translating research into action for diabetes (TRIAD).
Topics: Aged; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Male; Managed Care Programs; Middle Aged; Pioglitazone; Proportional Hazards Models; Prospective Studies; Risk Factors; Rosiglitazone; Thiazolidinediones | 2010 |
Meta-analysis for rare events.
Topics: Biostatistics; Cardiovascular Diseases; Humans; Hypoglycemic Agents; Likelihood Functions; Meta-Analysis as Topic; Models, Statistical; Myocardial Infarction; Poisson Distribution; Risk; Rosiglitazone; Thiazolidinediones | 2010 |
FDA committee urges tight restrictions on rosiglitazone.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug Approval; Humans; Hypoglycemic Agents; Rosiglitazone; Thiazolidinediones; United States; United States Food and Drug Administration | 2010 |
Don't mess with the DSMB.
Topics: Anticholesteremic Agents; Aortic Valve Stenosis; Azetidines; Cardiovascular Diseases; Clinical Trials Data Monitoring Committees; Diabetes Mellitus, Type 2; Ezetimibe; Humans; Hypoglycemic Agents; Neoplasms; Rosiglitazone; Simvastatin; Thiazolidinediones; United States | 2010 |
Drug safety. Planned study of Avandia in doubt after FDA review.
Topics: Cardiovascular Diseases; Diabetes Mellitus; Humans; Hypoglycemic Agents; Informed Consent; Patient Selection; Pioglitazone; Randomized Controlled Trials as Topic; Rosiglitazone; Thiazolidinediones; United States; United States Food and Drug Administration | 2010 |
Rosiglitazone and cardiovascular disease revisited.
Topics: Cardiovascular Diseases; Humans; Hypoglycemic Agents; Rosiglitazone; Thiazolidinediones | 2010 |
Licensing drugs for diabetes.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug Approval; Humans; Hypoglycemic Agents; Rosiglitazone; Safety-Based Drug Withdrawals; Thiazolidinediones | 2010 |
Commentary: What can we learn from the continuing regulatory focus on the thiazolidinediones?
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug Approval; Humans; Hypoglycemic Agents; Rosiglitazone; Safety-Based Drug Withdrawals; Thiazolidinediones; United States; United States Food and Drug Administration | 2010 |
Rosiglitazone: what went wrong?
Topics: Adverse Drug Reaction Reporting Systems; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Approval; Drug Industry; Humans; Hypoglycemic Agents; Rosiglitazone; Safety-Based Drug Withdrawals; Thiazolidinediones; United States; United States Food and Drug Administration | 2010 |
The Avandia debate: an unhappy conclusion.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Cardiomyopathies; Europe; Government Agencies; Humans; Hypoglycemic Agents; Insulin; Myocardial Infarction; Randomized Controlled Trials as Topic; Rosiglitazone; Thiazolidinediones; United States; United States Food and Drug Administration | 2010 |
Recent cardiovascular trials: what are the drivers of benefit and adverse effect?
Topics: Cardiovascular Diseases; Clinical Trials as Topic; Diabetic Angiopathies; Gliclazide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Incretins; Insulin; Rosiglitazone; Thiazolidinediones | 2009 |
[Rosiglitazone].
Topics: Cardiovascular Diseases; Contraindications; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Risk Factors; Rosiglitazone; Thiazolidinediones | 2010 |
Meta-analysis and moderation.
Topics: Cardiovascular Diseases; Humans; Meta-Analysis as Topic; Pioglitazone; Randomized Controlled Trials as Topic; Rosiglitazone; Scopolamine Derivatives; Thiazolidinediones; Tiotropium Bromide | 2010 |
Regulatory action on rosiglitazone by the U.S. Food and Drug Administration.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug and Narcotic Control; Humans; Myocardial Infarction; Rosiglitazone; Thiazolidinediones; United States; United States Food and Drug Administration | 2010 |
Therapy: What evidence should guide the use of thiazolidinediones?
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Humans; Randomized Controlled Trials as Topic; Risk Factors; Rosiglitazone; Thiazolidinediones; United States; United States Food and Drug Administration | 2010 |
Why the Avandia scandal proves big pharma needs stronger ethical standards.
Topics: Cardiovascular Diseases; Drug and Narcotic Control; Drug Evaluation; Drug Industry; Humans; Hypoglycemic Agents; Rosiglitazone; Thiazolidinediones; Trust; Truth Disclosure; United States | 2010 |
Serum sialic acid changes in type 2 diabetic patients on metformin or rosiglitazone treatment.
Topics: Biomarkers; Blood Glucose; Cardiovascular Diseases; Cholesterol; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Lipids; Male; Metformin; N-Acetylneuraminic Acid; Risk; Risk Factors; Rosiglitazone; Thiazolidinediones; Triglycerides | 2010 |
Diabetes: Breaking news! Rosiglitazone and cardiovascular risk.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Evidence-Based Medicine; Humans; Hypoglycemic Agents; Patient Selection; Risk Assessment; Risk Factors; Rosiglitazone; Thiazolidinediones | 2010 |
European drug regulators publish their evaluation of rosiglitazone.
Topics: Cardiovascular Diseases; Europe; Hypoglycemic Agents; Rosiglitazone; Safety-Based Drug Withdrawals; Thiazolidinediones | 2010 |
FDA puts restrictions on use of controversial diabetes drug.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug and Narcotic Control; Drug Approval; Drug Industry; Drug Prescriptions; Humans; Hypoglycemic Agents; Mifepristone; Rosiglitazone; Thiazolidinediones; United States; United States Food and Drug Administration | 2011 |
[Transparency in biomedical research: about the risks associated with the use of Avandia].
Topics: Biomedical Research; Cardiovascular Diseases; Chile; Conflict of Interest; Drug Industry; Humans; Hypoglycemic Agents; Research Personnel; Risk Factors; Rosiglitazone; Thiazolidinediones | 2010 |
Analytical issues regarding rosiglitazone meta-analysis.
Topics: Cardiovascular Diseases; Data Interpretation, Statistical; Humans; Hypoglycemic Agents; Meta-Analysis as Topic; Myocardial Infarction; Rosiglitazone; Thiazolidinediones | 2011 |
Switching from rosiglitazone: thinking outside the class.
Topics: Blood Glucose; Cardiovascular Diseases; Decision Making; Diabetes Mellitus; Drug Labeling; Evidence-Based Medicine; Heart Failure; Humans; Hypoglycemic Agents; Pioglitazone; Risk; Rosiglitazone; Thiazolidinediones | 2011 |
What have we learnt from the rosiglitazone saga?
Topics: Cardiovascular Diseases; Humans; Hypoglycemic Agents; Risk Factors; Rosiglitazone; Thiazolidinediones | 2011 |
Antidiabetic prescribing trends and predictors of thiazolidinedione discontinuation following the 2007 rosiglitazone safety alert.
Topics: Cardiovascular Diseases; Cohort Studies; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Male; Middle Aged; Pioglitazone; Retrospective Studies; Rosiglitazone; Thiazolidinediones; United States | 2011 |
Rosiglitazone saga. Should we throw the baby out with the bathwater?
Topics: Cardiovascular Diseases; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Rosiglitazone; Thiazolidinediones | 2011 |
Rosiglitazone saga. Demonisation of rosiglitazone.
Topics: Cardiovascular Diseases; Humans; Hypoglycemic Agents; Pioglitazone; Rosiglitazone; Thiazolidinediones | 2011 |
[Benefits and harms - two sides of the same medal?].
Topics: Cardiovascular Agents; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Approval; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Germany; Humans; Hypoglycemic Agents; Insurance, Pharmaceutical Services; Product Surveillance, Postmarketing; Risk Assessment; Rosiglitazone; Survival Analysis; Thiazolidinediones | 2011 |
[Glycemic control and cardiovascular benefit: what do we know today?].
Topics: Adult; Age Factors; Biomarkers; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Early Termination of Clinical Trials; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Middle Aged; Pioglitazone; Randomized Controlled Trials as Topic; Risk Factors; Rosiglitazone; Survival Analysis; Thiazolidinediones | 2011 |
[Drug correction of hormonal disturbances and risk factors of cardiovascular complications in women of reproductive age with polycystic ovary syndrome].
Topics: Biomarkers; Cardiovascular Diseases; Female; Follicle Stimulating Hormone; Follow-Up Studies; Humans; Incidence; Luteinizing Hormone; Polycystic Ovary Syndrome; PPAR gamma; Radioimmunoassay; Reproduction; Risk Factors; Rosiglitazone; Russia; Testosterone; Thiazolidinediones; Treatment Outcome; Young Adult | 2010 |
Intensive glucose lowering and cardiovascular outcomes.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Rosiglitazone; Thiazolidinediones | 2011 |
Rosiglitazone REMS arrives in November.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug Approval; Humans; Pharmacies; PPAR gamma; Risk Assessment; Rosiglitazone; Thiazolidinediones; United States; Vasodilator Agents | 2011 |
PPARγ activation induces acute PAI-1 gene expression in the liver but not in adipose tissues of diabetic model mice.
Topics: Adipose Tissue; Animals; Cardiovascular Diseases; Cell Line; Diabetes Mellitus, Experimental; Humans; Hypoglycemic Agents; Liver; Mice; Plasminogen Activator Inhibitor 1; PPAR gamma; RNA, Messenger; Rosiglitazone; Thiazolidinediones; Transcriptional Activation | 2011 |
Red wine: a source of potent ligands for peroxisome proliferator-activated receptor γ.
Topics: Binding, Competitive; Cardiovascular Diseases; Catechin; Coumaric Acids; Diabetes Mellitus, Type 2; Ellagic Acid; Flavonoids; Gas Chromatography-Mass Spectrometry; Humans; Hypoglycemic Agents; Ligands; Models, Chemical; Phenols; Plant Extracts; Polyphenols; PPAR gamma; Rosiglitazone; Spectroscopy, Fourier Transform Infrared; Thiazolidinediones; Wine | 2011 |
Pioglitazone is a valid alternative to rosiglitazone.
Topics: Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Europe; Humans; Hypoglycemic Agents; Pioglitazone; Rosiglitazone; Safety-Based Drug Withdrawals; Thiazolidinediones | 2011 |
Incidence of cardiovascular events in which 2 thiazolidinediones are used as add-on treatments for type 2 diabetes mellitus in a Taiwanese population.
Topics: Adult; Aged; Aged, 80 and over; Angina Pectoris; Antihypertensive Agents; Cardiovascular Diseases; Cerebrovascular Disorders; Chi-Square Distribution; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Heart Failure; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Incidence; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Pioglitazone; Proportional Hazards Models; Retrospective Studies; Risk Assessment; Risk Factors; Rosiglitazone; Taiwan; Thiazolidinediones; Time Factors; Treatment Outcome | 2011 |
Risk of death and cardiovascular outcomes with thiazolidinediones: a study with the general practice research database and secondary care data.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Cardiovascular Diseases; Cohort Studies; Databases, Factual; Diabetes Complications; Diabetes Mellitus; Female; Heart Failure; Hospitalization; Humans; Insulin; Male; Metformin; Middle Aged; Pioglitazone; Risk; Rosiglitazone; Stroke; Thiazolidinediones; Treatment Outcome | 2011 |
Physiological responses to acute psychological stress are reduced by the PPARγ agonist rosiglitazone.
Topics: Administration, Oral; Animals; Cardiovascular Diseases; Corticosterone; Hypoglycemic Agents; Hypothalamus; Immunohistochemistry; Male; PPAR gamma; Proto-Oncogene Proteins c-fos; Rats; Rats, Long-Evans; Rosiglitazone; Signal Transduction; Stress, Psychological; Thiazolidinediones | 2012 |
Viewpoint: Central adjudication of myocardial infarction in outcome-driven clinical trials--common patterns in TRITON, RECORD, and PLATO?
Topics: Acute Coronary Syndrome; Adenosine; Cardiovascular Diseases; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Judgment; Metformin; Multicenter Studies as Topic; Myocardial Infarction; Observer Variation; Outcome Assessment, Health Care; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Process Assessment, Health Care; Randomized Controlled Trials as Topic; Rosiglitazone; Stroke; Sulfonylurea Compounds; Thiazolidinediones; Thiophenes; Ticagrelor | 2012 |
Prescribing pattern of glucose lowering drugs in the United Kingdom in the last decade: a focus on the effects of safety warnings about rosiglitazone.
Topics: Aged; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug Labeling; Drug Prescriptions; Drug Substitution; Female; Humans; Hypoglycemic Agents; Male; Middle Aged; Pioglitazone; Practice Patterns, Physicians'; Risk Factors; Rosiglitazone; Thiazolidinediones; United Kingdom | 2013 |
Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus.
Topics: Biomarkers; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Humans; Lipids; Rosiglitazone; Thiazoles; Thiazolidinediones | 2003 |
[Insulin resistance increases risk of infarct. Glitazone now approved also for monotherapy].
Topics: Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Drug Approval; Germany; Humans; Hypoglycemic Agents; Insulin Resistance; Rosiglitazone; Survival Rate; Thiazolidinediones | 2003 |
[An overweight diabetic does not tolerate metformin. Insulin sensitizer can be prescribed alone, too].
Topics: Blood Glucose; C-Reactive Protein; Cardiovascular Diseases; Cholesterol, HDL; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Resistance; Obesity; Placebos; Risk Factors; Rosiglitazone; Thiazolidinediones; Time Factors | 2003 |
C-reactive protein attenuates endothelial progenitor cell survival, differentiation, and function: further evidence of a mechanistic link between C-reactive protein and cardiovascular disease.
Topics: Apoptosis; C-Reactive Protein; Cardiovascular Diseases; Cell Differentiation; Cells, Cultured; Endothelial Cells; Enzyme Induction; Gene Expression Regulation; Humans; Inflammation; Male; Neovascularization, Physiologic; Nitric Oxide; Nitric Oxide Synthase; Nitric Oxide Synthase Type III; Receptors, Cytoplasmic and Nuclear; Recombinant Proteins; Rosiglitazone; Thiazolidinediones; Transcription Factors; Vascular Endothelial Growth Factor A | 2004 |
[PPARgamma agonists--antidiabetics with positive effects on cardiovascular risk?].
Topics: Albuminuria; Atherosclerosis; Blood Pressure; Cardiovascular Diseases; Glucose; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Lipoproteins; Pioglitazone; PPAR gamma; Risk Factors; Rosiglitazone; Thiazolidinediones | 2005 |
Optimal treatments for the metabolic syndrome.
Topics: Anti-Obesity Agents; Cardiovascular Diseases; Complementary Therapies; Diabetes Mellitus; Diet; Health Behavior; Humans; Hypoglycemic Agents; Life Style; Metabolic Syndrome; Metformin; Obesity; Piperidines; Pyrazoles; Randomized Controlled Trials as Topic; Rimonabant; Rosiglitazone; Thiazolidinediones | 2006 |
Acute-phase serum amyloid A: an inflammatory adipokine and potential link between obesity and its metabolic complications.
Topics: Adipocytes; Adipose Tissue; Animals; Biomarkers; Cardiovascular Diseases; Cell Line; Clinical Trials as Topic; Cross-Sectional Studies; Cytokines; Dose-Response Relationship, Drug; Female; Humans; Hypoglycemic Agents; Inflammation; Lipolysis; Male; Mice; Mice, Inbred C57BL; Middle Aged; Obesity; Risk Factors; RNA, Messenger; Rosiglitazone; Serum Amyloid A Protein; Stromal Cells; Thiazolidinediones | 2006 |
[Effects of rosiglitazone on endothelial function in non-diabetic subjects with metabolic syndrome].
Topics: Adult; Biomarkers; Cardiovascular Diseases; Case-Control Studies; Endothelium, Vascular; Female; Humans; Hypoglycemic Agents; Inflammation; Male; Metabolic Syndrome; Risk Factors; Rosiglitazone; Thiazolidinediones; Vasodilation; Vasodilator Agents | 2006 |
The DREAM trial.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Rosiglitazone; Thiazolidinediones | 2006 |
Increased atherosclerosis following treatment with a dual PPAR agonist in the ApoE knockout mouse.
Topics: Animals; Apolipoproteins E; Atherosclerosis; Blood Pressure; Cardiovascular Diseases; Cell Adhesion; Gemfibrozil; Gene Expression Profiling; Lipids; Male; Mice; Mice, Knockout; Peroxisome Proliferator-Activated Receptors; Rosiglitazone; Thiazolidinediones | 2007 |
Rosiglitazone and cardiovascular risk.
Topics: Adverse Drug Reaction Reporting Systems; Cardiovascular Diseases; Clinical Trials, Phase IV as Topic; Diabetes Mellitus, Type 2; Drug Approval; Humans; Hypoglycemic Agents; Meta-Analysis as Topic; Myocardial Infarction; Randomized Controlled Trials as Topic; Risk Assessment; Rosiglitazone; Thiazolidinediones; United States; United States Food and Drug Administration | 2007 |
Man on a mission.
Topics: Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus; History, 21st Century; Humans; Lactones; Quinolines; Rosiglitazone; Sulfones; Thiazolidinediones | 2007 |
Rosiglitazone--continued uncertainty about safety.
Topics: Cardiovascular Diseases; Confidence Intervals; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Myocardial Infarction; Rosiglitazone; Thiazolidinediones | 2007 |
Rosiglitazone and cardiotoxicity--weighing the evidence.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Heart Failure; Humans; Hypoglycemic Agents; Metformin; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones | 2007 |
The record on rosiglitazone and the risk of myocardial infarction.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug Approval; Drug Labeling; Hospitalization; Humans; Hypoglycemic Agents; Meta-Analysis as Topic; Middle Aged; Myocardial Infarction; Product Surveillance, Postmarketing; Research Design; Rosiglitazone; Thiazolidinediones; United States | 2007 |
Faster publication isn't always better.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Meta-Analysis as Topic; Myocardial Infarction; Peer Review, Research; Publishing; Randomized Controlled Trials as Topic; Research Design; Rosiglitazone; Thiazolidinediones; Time Factors | 2007 |
High incidence of reduced plasma HDL cholesterol in diabetic patients treated with rosiglitazone and fibrate.
Topics: Adult; Aged; Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol, HDL; Clofibric Acid; Diabetes Complications; Diabetes Mellitus; Dose-Response Relationship, Drug; Drug Interactions; Female; Humans; Hypoglycemic Agents; Incidence; Male; Middle Aged; Retrospective Studies; Risk Factors; Rosiglitazone; Thiazolidinediones | 2007 |
Uncertain effects of rosiglitazone on the risk for myocardial infarction and cardiovascular death.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Meta-Analysis as Topic; Myocardial Infarction; PPAR gamma; Research Design; Risk Factors; Rosiglitazone; Thiazolidinediones | 2007 |
Keeping science on top in drug evaluation.
Topics: Advisory Committees; Cardiovascular Diseases; Conflict of Interest; Cyclooxygenase Inhibitors; Dexfenfluramine; Drug Approval; Drug Evaluation; Drug Industry; Etoricoxib; Humans; Hypoglycemic Agents; Lactones; Pyridines; Risk; Rosiglitazone; Sulfones; Thiazolidinediones; United States; United States Food and Drug Administration | 2007 |
Outlook on diabetes drug less than rosy. Early work suggests that rosiglitazone (Avandia) may not be best for the heart.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Myocardial Infarction; Rosiglitazone; Thiazolidinediones | 2007 |
Heart failure risk prompts warning labels on diabetes drugs. The concern now is whether this particular class of drugs causes other cardiovascular problems.
Topics: Cardiovascular Diseases; Humans; Hypoglycemic Agents; Pioglitazone; Rosiglitazone; Thiazolidinediones | 2007 |
The Avandia debate.
Topics: Cardiovascular Agents; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus; Humans; Hypoglycemic Agents; Myocardial Infarction; Rosiglitazone; Thiazolidinediones | 2007 |
Rosiglitazone and the FDA.
Topics: Advisory Committees; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug Approval; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Rosiglitazone; Thiazolidinediones; United States; United States Food and Drug Administration | 2007 |
Rosiglitazone and cardiovascular risk.
Topics: Cardiovascular Diseases; Data Interpretation, Statistical; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Myocardial Infarction; Odds Ratio; Risk; Rosiglitazone; Thiazolidinediones | 2007 |
Fixed vs random effects meta-analysis in rare event studies: the rosiglitazone link with myocardial infarction and cardiac death.
Topics: Cardiovascular Diseases; Humans; Hypoglycemic Agents; Logistic Models; Meta-Analysis as Topic; Models, Statistical; Myocardial Infarction; Odds Ratio; Proportional Hazards Models; Risk Factors; Rosiglitazone; Thiazolidinediones | 2007 |
Rosiglitazone and cardiovascular risk.
Topics: Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Practice Patterns, Physicians'; Rosiglitazone; Thiazolidinediones | 2007 |
Rosiglitazone and cardiovascular risk.
Topics: Bayes Theorem; Cardiovascular Diseases; Data Interpretation, Statistical; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Meta-Analysis as Topic; Myocardial Infarction; Odds Ratio; Risk; Rosiglitazone; Thiazolidinediones | 2007 |
Rosiglitazone and cardiovascular risk.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Meta-Analysis as Topic; Myocardial Infarction; Risk; Rosiglitazone; Thiazolidinediones | 2007 |
Cardiovascular risk and the thiazolidinediones: déjà vu all over again?
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Pioglitazone; Risk; Rosiglitazone; Thiazolidinediones | 2007 |
Perspective: effect of rosiglitazone on cardiovascular outcomes.
Topics: Cardiovascular Diseases; Humans; Hypoglycemic Agents; Myocardial Infarction; Odds Ratio; PPAR gamma; Risk Assessment; Rosiglitazone; Thiazolidinediones | 2007 |
Rosiglitazone: a thunderstorm from scarce and fragile data.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Meta-Analysis as Topic; Myocardial Infarction; Research Design; Rosiglitazone; Thiazolidinediones | 2007 |
[Rosiglitazone--statistics for benefits and problems].
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Meta-Analysis as Topic; Randomized Controlled Trials as Topic; Risk Factors; Rosiglitazone; Thiazolidinediones | 2007 |
The Avandia debacle: methodology and practical importance of the findings.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Middle Aged; Myocardial Infarction; Randomized Controlled Trials as Topic; Risk Assessment; Rosiglitazone; Thiazolidinediones | 2007 |
Thiazolidinediones and clinical diabetes management: new challenges for the fall of 2007.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Middle Aged; Myocardial Infarction; Randomized Controlled Trials as Topic; Risk Assessment; Rosiglitazone; Thiazolidinediones | 2007 |
[Antidiabetic with increased risk of coronary disease].
Topics: Cardiovascular Diseases; Humans; Hypoglycemic Agents; Risk Factors; Rosiglitazone; Thiazolidinediones | 2007 |
Meta-analysis of small trials: proceed with caution.
Topics: Cardiovascular Diseases; Clinical Trials as Topic; Evidence-Based Medicine; Humans; Hypoglycemic Agents; Meta-Analysis as Topic; Rosiglitazone; Thiazolidinediones | 2007 |
[Determining the current position regarding the value of pioglitazone for the therapy of diabetes].
Topics: Animals; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dyslipidemias; Fractures, Bone; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Resistance; Lipids; Osteoporosis, Postmenopausal; Pioglitazone; PPAR gamma; Risk Assessment; Risk Factors; Rosiglitazone; Thiazolidinediones | 2007 |
Cardiovascular safety of low-dose rosiglitazone.
Topics: Cardiovascular Diseases; Diabetes Mellitus; Humans; Hypoglycemic Agents; Rosiglitazone; Thiazolidinediones; Treatment Outcome | 2008 |
[Glitazone - mailing no 4. In response to DMW 49/2007].
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Pioglitazone; Rosiglitazone; Thiazolidinediones | 2008 |
A novel selective peroxisome proliferator-activator receptor-gamma modulator-SPPARgammaM5 improves insulin sensitivity with diminished adverse cardiovascular effects.
Topics: 3T3-L1 Cells; Acetates; Adipose Tissue, White; Animals; Cardiomegaly; Cardiovascular Diseases; Chlorocebus aethiops; COS Cells; Diabetes Mellitus, Type 2; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Partial Agonism; Gene Expression Profiling; Gene Expression Regulation; Hemodilution; Humans; Hypoglycemic Agents; Indoles; Insulin Resistance; Male; Mice; Mice, Inbred Strains; PPAR alpha; PPAR delta; PPAR gamma; Propionates; Protein Binding; Rats; Rats, Zucker; Rosiglitazone; Thiazolidinediones; Transcriptional Activation; Transfection; Water-Electrolyte Balance | 2008 |
Controversy over the cardiovascular effects of thiazolidinediones.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Follow-Up Studies; Humans; Hyperglycemia; Insulin Resistance; Myocardial Infarction; Randomized Controlled Trials as Topic; Risk Assessment; Rosiglitazone; Survival Rate; Thiazolidinediones | 2008 |
Development of a diabetes treatment simulation model: with application to assessing alternative treatment intensification strategies on survival and diabetes-related complications.
Topics: Amputation, Surgical; Blindness; Cardiovascular Diseases; Computer Simulation; Diabetes Complications; Diabetes Mellitus, Type 2; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Metformin; Models, Biological; Prognosis; Renal Insufficiency; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones; United Kingdom | 2008 |
Rosiglitazone (Avandia): hepatic, cardiac and hematological reactions.
Topics: Aged; Cardiovascular Diseases; Chemical and Drug Induced Liver Injury; Female; Hematologic Diseases; Humans; Hypoglycemic Agents; Liver Failure; Male; Middle Aged; Rosiglitazone; Thiazoles; Thiazolidinediones | 2001 |
Relationship between insulin resistance and an endogenous nitric oxide synthase inhibitor.
Topics: Adult; Aged; Arginine; Cardiovascular Diseases; Cross-Sectional Studies; Enzyme Inhibitors; Female; Humans; Hypertension; Hypoglycemic Agents; Lipoproteins; Male; Metabolic Diseases; Metabolic Syndrome; Middle Aged; Nitric Oxide Synthase; Regression Analysis; Risk Factors; Rosiglitazone; Thiazoles; Thiazolidinediones; Vasodilator Agents | 2002 |